At the 2026 National Breast Cancer Conference in Beijing, Professor Zhang Qingyuan of Harbin Medical University Cancer Hospital broke down the most important updates for younger women facing breast cancer. The newly released CSCO Breast Cancer Guidelines shift the focus from treating “by type” to treating “by marker,” demanding stricter testing of classic receptors (ER, PR, HER2) and, crucially, expanding routine checks for driver‑gene mutations such as PIK3CA, AKT1 and ESR1. This precision approach helps doctors spot patients who could benefit from targeted drugs—PI3K inhibitors, AKT inhibitors, and next‑generation SERDs—earlier in the disease course, potentially delaying resistance and improving survival. Professor Zhang also highlighted three practical coping strategies for the rising tide of younger patients: (1) fertility‑preserving options that let women keep the chance of future pregnancy; (2) domestically developed innovative therapies, including a “living drug reservoir” that simultaneously attacks tumors and promotes breast tissue regeneration; and (3) refined risk‑stratification tools that guide clinicians in selecting the most effective, low‑toxicity regimens. Together, these advances promise a more personalized, hopeful outlook for young women navigating breast cancer treatment.
Read moreA new five‑year follow‑up study shows that CAR‑T cell therapy is dramatically changing outcomes for patients with relapsed or refractory mantle‑cell lymphoma, a disease that has long been difficult to treat. Researchers also highlighted several breakthroughs that could make CAR‑T safer and more effective across blood cancers. First, experts warned that the FDA’s 2024 definition of dose‑limiting toxicity (DLT) for early‑stage CAR‑T trials is overly strict, ignoring how quickly side‑effects like cytokine release syndrome (CRS) and brain inflammation (ICANS) can resolve. This rigidity might slow progress in the field. Next, a team at Peking University People’s Hospital compared three scoring systems (CAR‑HT, ALL‑HT, and eIPM) and found they reliably predict severe blood‑related toxicities and survival after CAR‑T in leukemia, lymphoma, and multiple myeloma patients. Yale scientists introduced an “IDR‑CAR” fusion protein that helps CAR‑T cells recognize and kill cancer cells even when the target antigen is low, boosting potency in lab and animal tests. Researchers in Chengdu emphasized the power of biomarkers to pick the right patients, monitor treatment, and fine‑tune CAR‑T therapy. At the 2025 ASH meeting, data showed CAR‑T moving into first‑line treatment for multiple myeloma, delivering unprecedented response rates in both newly diagnosed and relapsed cases. Finally, a Phase 1 trial of a fourth‑generation CD19 CAR‑T that also releases IL‑10 reported a 100% overall response and complete molecular remission in 12 patients with relapsed B‑ALL, with manageable side effects, pointing to a promising strategy to overcome resistance.
Read more